Annual EBITDA
-$226.76 M
-$57.72 M-34.15%
December 31, 2023
Summary
- As of February 12, 2025, LYEL annual EBITDA is -$226.76 million, with the most recent change of -$57.72 million (-34.15%) on December 31, 2023.
- During the last 3 years, LYEL annual EBITDA has fallen by -$19.11 million (-9.21%).
- LYEL annual EBITDA is now -124.88% below its all-time high of -$100.83 million, reached on December 31, 2019.
Performance
LYEL EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$45.83 M
+$802.00 K+1.72%
September 30, 2024
Summary
- As of February 12, 2025, LYEL quarterly EBITDA is -$45.83 million, with the most recent change of +$802.00 thousand (+1.72%) on September 30, 2024.
- Over the past year, LYEL quarterly EBITDA has increased by +$8.63 million (+15.84%).
- LYEL quarterly EBITDA is now -370.34% below its all-time high of -$9.74 million, reached on December 31, 2022.
Performance
LYEL Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$197.45 M
+$8.11 M+3.95%
September 30, 2024
Summary
- As of February 12, 2025, LYEL TTM EBITDA is -$197.45 million, with the most recent change of +$8.11 million (+3.95%) on September 30, 2024.
- Over the past year, LYEL TTM EBITDA has increased by +$29.30 million (+12.92%).
- LYEL TTM EBITDA is now -512.68% below its all-time high of -$32.23 million, reached on March 31, 2020.
Performance
LYEL TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
LYEL EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -34.1% | +15.8% | +12.9% |
| 3 y3 years | -9.2% | -6.6% | +1.8% |
| 5 y5 years | -124.9% | +23.2% | -5.6% |
LYEL EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -34.1% | at low | -370.3% | +28.8% | -21.8% | +12.9% |
| 5 y | 5-year | -124.9% | at low | -370.3% | +54.9% | -512.7% | +13.7% |
| alltime | all time | -124.9% | at low | -370.3% | +54.9% | -512.7% | +13.7% |
Lyell Immunopharma EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$45.83 M(-1.7%) | -$197.45 M(-3.9%) |
| Jun 2024 | - | -$46.63 M(-7.8%) | -$205.56 M(-6.5%) |
| Mar 2024 | - | -$50.55 M(-7.2%) | -$219.78 M(-3.1%) |
| Dec 2023 | -$226.76 M(+34.1%) | -$54.45 M(+1.0%) | -$226.76 M(+24.6%) |
| Sep 2023 | - | -$53.94 M(-11.4%) | -$182.05 M(-4.1%) |
| Jun 2023 | - | -$60.84 M(+5.8%) | -$189.93 M(+17.1%) |
| Mar 2023 | - | -$57.53 M(+490.5%) | -$162.18 M(-4.1%) |
| Dec 2022 | -$169.04 M | -$9.74 M(-84.2%) | -$169.04 M(-16.4%) |
| Sep 2022 | - | -$61.82 M(+86.8%) | -$202.27 M(+9.0%) |
| Jun 2022 | - | -$33.09 M(-48.6%) | -$185.52 M(-12.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | -$64.39 M(+49.8%) | -$212.13 M(+5.5%) |
| Dec 2021 | -$201.15 M(-3.1%) | -$42.97 M(-4.7%) | -$201.15 M(+2.5%) |
| Sep 2021 | - | -$45.07 M(-24.5%) | -$196.25 M(+5.0%) |
| Jun 2021 | - | -$59.70 M(+11.8%) | -$186.92 M(-18.3%) |
| Mar 2021 | - | -$53.41 M(+40.3%) | -$228.83 M(+10.2%) |
| Dec 2020 | -$207.64 M(+105.9%) | - | - |
| Dec 2020 | - | -$38.07 M(+6.5%) | -$207.64 M(+22.5%) |
| Sep 2020 | - | -$35.74 M(-64.8%) | -$169.57 M(+26.7%) |
| Jun 2020 | - | -$101.60 M(+215.3%) | -$133.83 M(+315.3%) |
| Mar 2020 | - | -$32.23 M | -$32.23 M |
| Dec 2019 | -$100.83 M | - | - |
FAQ
- What is Lyell Immunopharma annual EBITDA?
- What is the all time high annual EBITDA for Lyell Immunopharma?
- What is Lyell Immunopharma annual EBITDA year-on-year change?
- What is Lyell Immunopharma quarterly EBITDA?
- What is the all time high quarterly EBITDA for Lyell Immunopharma?
- What is Lyell Immunopharma quarterly EBITDA year-on-year change?
- What is Lyell Immunopharma TTM EBITDA?
- What is the all time high TTM EBITDA for Lyell Immunopharma?
- What is Lyell Immunopharma TTM EBITDA year-on-year change?
What is Lyell Immunopharma annual EBITDA?
The current annual EBITDA of LYEL is -$226.76 M
What is the all time high annual EBITDA for Lyell Immunopharma?
Lyell Immunopharma all-time high annual EBITDA is -$100.83 M
What is Lyell Immunopharma annual EBITDA year-on-year change?
Over the past year, LYEL annual EBITDA has changed by -$57.72 M (-34.15%)
What is Lyell Immunopharma quarterly EBITDA?
The current quarterly EBITDA of LYEL is -$45.83 M
What is the all time high quarterly EBITDA for Lyell Immunopharma?
Lyell Immunopharma all-time high quarterly EBITDA is -$9.74 M
What is Lyell Immunopharma quarterly EBITDA year-on-year change?
Over the past year, LYEL quarterly EBITDA has changed by +$8.63 M (+15.84%)
What is Lyell Immunopharma TTM EBITDA?
The current TTM EBITDA of LYEL is -$197.45 M
What is the all time high TTM EBITDA for Lyell Immunopharma?
Lyell Immunopharma all-time high TTM EBITDA is -$32.23 M
What is Lyell Immunopharma TTM EBITDA year-on-year change?
Over the past year, LYEL TTM EBITDA has changed by +$29.30 M (+12.92%)